Bone Marrow Transplantation

Papers
(The H4-Index of Bone Marrow Transplantation is 28. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Trading tissues for freedom: incentivizing stem cell and solid organ donation in the incarcerated population277
Measurable residual disease for secondary acute myeloid leukemia prior to allogeneic hematopoietic cell transplantation: does it make a difference?171
Prognostic impact of HLA supertype mismatch in single-unit cord blood transplantation113
Cardiorespiratory fitness and physical performance after childhood hematopoietic stem cell transplantation: a systematic review and meta-analysis65
Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy57
Reduced-toxicity myeloablative conditioning regimen using fludarabine and full doses of intravenous busulfan in pediatric patients not eligible for standard myeloablative conditioning regimens: Result53
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Poster Session (P613-P616)52
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards52
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency48
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO006)46
When is a chimaera not a chimaera?45
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Statistical Symposium - Poster Session (P611-P612)43
Mild clinical course of SARS-coronavirus-2 infection early posttransplant in patients with adoptively transferred antibody response42
Day 100 risk assessment tool predicts overall survival in allogeneic hematopoietic cell transplantation42
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: statistical symposium-poster session (P188–P189)39
Risk factors for chronic kidney disease following acute kidney injury in pediatric allogeneic hematopoietic cell transplantation38
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Nurses Group – Oral Session (NO001 – NO010)36
The 47th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group - Oral Session (O170-O171)35
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany33
Pre-engraftment Cytomegalovirus DNAemia after allogeneic hematopoietic stem cell transplantation and its impact on engraftment33
Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation33
Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation32
Prognostic impact of chromosomal changes at relapse after allogeneic hematopoietic cell transplantation for acute myeloid leukemia or myelodysplastic syndrome31
Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation31
Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation29
Standardized translations of the Lee Chronic GvHD Symptom Scale to 12 European languages: an EU COST Action cGvHD Eurograft project28
Alemtuzumab-based conditioning regimen before hematopoietic stem cell transplantation in patients with short telomere syndromes: a retrospective study of the SFGM-TC28
Challenges and successes in cellular therapies and CAR-T: insights from the 50th EBMT annual meeting28
Comparative analysis of reduced toxicity conditioning regimens between fludarabine plus melphalan and fludarabine plus busulfex in adult patients with acute lymphoblastic leukemia28
0.085446119308472